Bietaserpine

This classification denotes an antihypertensive agent with the molecular formula C39H53N3O9, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0P5B94FVD5, chemically known as 3-beta,20-alpha-yohimban-16-beta-carboxylic acid, 1-(2-(diethylamino)ethyl)-18-beta-hydroxy-11,17-alpha-dimethoxy-, methyl ester, 3,4,5-trimethoxybenzoate (ester) but generally known as bietaserpine, which bears US NIH Compound Identifier 65518. Bietaserpine most often comes in base and bitartrate forms. European Medicines Agency schedules Bietaserpine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05826MIG. The term BIETASERPINE is an International Non-Proprietary Name. World Health Organization schedules bietaserpine in its Anatomical Therapeutic Chemical (ATC) Classification. BIETASERPINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule bietaserpine under HS 29399900 and SITC 54149. As of Q4 2014, BIETASERPINE remains the US FDA Preferred Term for this commodity. Bietaserpine bears US NLM identifiers UMLS ID C0053565 and NCI Concept Code C72973. SMILES: O(C1C(C2C(CN3C(C2)c2n(c4c(c2CC3)ccc(OC)c4)CCN(CC)CC)CC1OC(=O)c1cc(OC)c(OC)c(OC)c1)C(=O)OC)C.